CSF3 and non-small cell lung carcinoma: In the light of these previous studies, we conducted a phase I study of escalating dose of irinotecan combined with a fixed schedule of cisplatin and ifosfamide with recombinant human granulocyte colony stimulating factor (rhG-CSF) support in advanced NSCLC (Fujita et al, 1999).